Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2023-06-06 Capital/Financing Update
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
First Patient Dosed for Phase 1, Pain Indication IRX211 2 pages 197.9KB
Capital/Financing Update Classification · 90% confidence The document is a company announcement about a milestone achieved in a Phase 1 clinical trial for a drug candidate IRX211. It details the dosing of the first patient, trial design, regulatory interactions, and future plans. There are no financial statements, no detailed financial performance data, no earnings results, no management discussion of financial results, and no regulatory filings or certifications. The document is a progress update on clinical development and regulatory strategy, typical of a Capital/Financing Update or general corporate announcement. It is not an Annual Report, Interim Report, Earnings Release, nor a Regulatory Filing. Given the focus on clinical trial progress and regulatory pathway, the best fitting category is Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, and often includes clinical trial progress announcements as they relate to company value and financing prospects. Confidence is high as the document is a milestone announcement related to drug development progress, which is a common type of Capital/Financing Update.
2023-06-06 English
Constitution 49 pages 877.0KB
Governance Information Classification · 100% confidence The document is an ASX announcement dated 6 June 2023 regarding the amended Constitution of InhaleRx Limited, approved by shareholders at the Annual General Meeting held on 26 May 2023. The text includes the full amended Constitution document, which is a governance document detailing the company's internal rules and structure. It is not a report of financial performance, audit, or earnings, nor is it a brief announcement or a proxy solicitation. The document is lengthy (15,000 characters) and contains the full constitution text, indicating it is the actual governance document rather than a mere announcement or summary. Therefore, the most appropriate classification is Governance Information (CGR).
2023-06-05 English
Chairman's Address to Shareholders 2 pages 202.8KB
AGM Information Classification · 95% confidence The document is titled 'Chairman’s address to AGM' and is dated 26 May 2023. It is an ASX announcement related to the Annual General Meeting (AGM) of InhaleRx Ltd. The content includes a summary of the company's progress during the 2022 year, highlights of clinical trial developments, capital raising, and resolutions to be considered at the AGM. It also mentions the appointment of a new auditor and financial loss figures for the year ended 31 December 2022. The document is a speech or address given at the AGM rather than a full annual report or financial statement. It is not a standalone audit report, earnings release, or other specific filing type. Given the nature of the content and the title, this document fits best under AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document length (6403 characters) supports it being a detailed AGM address rather than a brief announcement or report publication notice.
2023-05-25 English
AGM Presentation 17 pages 1.6MB
AGM Information Classification · 95% confidence The document is a detailed presentation titled 'Investor update presentation Annual General Meeting May 2023' for InhaleRx Limited. It contains extensive information about the company's business, clinical programs, regulatory updates, management and board details, and strategic plans. The content is structured as a presentation aimed at investors, focusing on company strategy, clinical progress, and regulatory pathways, typical of materials shared at an Annual General Meeting (AGM). There is no indication that this is a full annual report, earnings release, or regulatory filing. The presence of the phrase 'Investor update presentation Annual General Meeting May 2023' strongly suggests this is presentation material for the AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2023-05-25 English
Results of Meeting 2 pages 149.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 26 May 2023, titled 'Results of Meeting'. It provides detailed poll voting results for resolutions put to shareholders at the Annual General Meeting (AGM) of InhaleRx Limited. The content includes proxy votes and poll results for various resolutions such as adoption of remuneration report, election of director, approval of future equity securities, removal and appointment of auditor, and amendment of constitution. The document is focused on the official results of shareholder votes at the AGM, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 2987 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, the appropriate classification is DVA with high confidence.
2023-05-25 English
Quarterly Appendix 4C Cash Flow Report 5 pages 220.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 31 March 2023. It includes actual financial data such as cash flows, reconciliation of cash and cash equivalents, payments to related parties, and estimated cash available for future operating activities. The document is over 10,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of detailed quarterly financial data and compliance statements aligns with the characteristics of an Interim / Quarterly Report. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.